Compare DexCom, Inc. (DXCM) vs HSBC Holdings plc (HSBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs HSBC Holdings plc — how do they compare? DexCom, Inc. trades at $77.28 (market cap $28.06B), while HSBC Holdings plc trades at $100.7 (market cap $334.99B). The key difference: HSBC Holdings plc is far larger — about 11.9× DexCom, Inc.'s market cap, and HSBC Holdings plc pays a 3.73% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | HSBC | |
|---|---|---|
Market Cap | $28.06B | $334.99B |
Sector | Health | Technology |
52-Week High | $89.53 | $100.46 |
52-Week Low | $54.84 | $61.30 |
Enterprise Value | $27.03B | — |
Dividend Yield | — | 3.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
HSBC trades at $100.72, up 1.48% today, near its 52-week high. Technical indicators show a bullish trend with support at $100 and resistance at $101. The company reported $22.29B net income for 2025 with a 30.81% net margin, though Q1 2026 EPS missed expectations. Recent news highlights strategic moves including a potential Turkey business sale and AI partnerships.
The outlook is cautiously optimistic with strong profitability and analyst buy ratings (38.1%), but risks include execution of global restructuring and regulatory penalties. Earnings growth and strategic focus on core markets are key catalysts for upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →
